GlassScriptPhysician profile
James H Prieto
NPI 1154580769
$16,214.16
in general payments reported to CMS, 2019-2025
27 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,319 · 2020: $9,856 · 2021: $2,475 · 2022: $973 · 2023: $339 · 2024: $823 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,920.48 | 2019-2025 | Da Vinci Surgical System |
| Ethicon US, LLC | $498.19 | 2019-2025 | Harmonic, Enseal, Proximate |
| Medtronic, INC. | $494.91 | 2021-2024 | Interstim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $479.17 | 2019-2023 | Xifaxan |
| Davol INC. | $459.43 | 2021-2025 | Phasix Mesh, Arista Ah Flexitip, Arista |
| Biom'Up Sa | $299.81 | 2019 | |
| Covidien LP | $277.04 | 2019 | |
| Braintree Laboratories, INC. | $259.91 | 2019-2024 | Suflave, Sutab |
| Baxter Healthcare | $194.70 | 2023-2025 | Seprafilm, Perclot, Tisseel |
| Smith+Nephew, INC. | $180.87 | 2019-2022 | |
| Biom'Up France Sas | $148.82 | 2021 | |
| Redhill Biopharma INC. | $145.79 | 2020-2022 | |
| Myriad Genetic Laboratories, INC. | $143.91 | 2023-2024 | Colaris |
| Pacira Pharmaceuticals Incorporated | $135.70 | 2024 | Exparel |
| Gi Supply, INC. | $131.97 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $110.14 | 2022-2025 | Gattex |
| Aroa Biosurgery Incorporated | $50.66 | 2025 | |
| Aimmune Therapeutics, INC. | $49.96 | 2024 | |
| Acell, INC. | $36.67 | 2019 | |
| Olympus America INC. | $34.08 | 2019 | |
| Stryker Corporation | $30.65 | 2023 | Spy-Phi System |
| Integra Lifesciences Corporation | $25.51 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Tela Bio, INC. | $24.83 | 2022 | |
| Heron Therapeutics, INC. | $24.24 | 2025 | Zynrelef |
| Shire North American Group INC | $20.10 | 2019 | |
| Ambu INC. | $18.40 | 2024 | |
| Kerecis Limited | $18.22 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Prieto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.